Patents by Inventor Rodney Flores-Lefranc

Rodney Flores-Lefranc has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multivalent CD20-binding molecule comprising Shiga toxin A subunit effector polypeptides and enriched compositions thereof
    Patent number: 11248061
    Abstract: Provided herein are multivalent CD20-binding molecules, and compositions thereof, for use in selective killing of specific cell types and/or as therapeutics for the treatment of a variety of diseases, including cancer, tumors, and immune disorders. Certain multivalent CD20-binding molecules can be used to deliver agents into CD20-expressing cells, collecting diagnostic information, and/or monitoring the treatment of diseases, such as cancers, tumors, and immune disorders.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: February 15, 2022
    Assignee: Molecular Templates, Inc.
    Inventors: Eric Poma, Erin Willert, Jason Kim, Jack Higgins, Jensing Liu, Rodney Flores-Lefranc
  • Multivalent CD20-binding molecules comprising Shiga toxin a subunit effector regions and enriched compositions thereof
    Patent number: 11104707
    Abstract: The present invention provides multivalent CD20-binding molecules and compositions thereof, such as enriched compositions comprising large proportions of multivalent CD20-binding molecules relative to monovalent CD20-binding molecules. Certain multivalent CD20-binding molecules of the present invention comprise (i) two or more CD20-binding regions and (ii) one or more Shiga toxin effector polypeptide regions derived from an A Subunit of a member of the Shiga toxin family. Certain multivalent CD20-binding molecules of the present invention, and compositions thereof, have uses for selective killing of specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, tumors, and immune disorders.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: August 31, 2021
    Assignee: Molecular Templates, Inc.
    Inventors: Eric Poma, Erin Willert, Jason Kim, Jack Higgins, Jensing Liu, Rodney Flores-Lefranc
  • MULTIVALENT CD20-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS AND ENRICHED COMPOSITIONS THEREOF
    Publication number: 20190359657
    Abstract: The present invention provides multivalent CD20-binding molecules and compositions thereof, such as enriched compositions comprising large proportions of multivalent CD20-binding molecules relative to monovalent CD20-binding molecules. Certain multivalent CD20-binding molecules of the present invention comprise (i) two or more CD20-binding regions and (ii) one or more Shiga toxin effector polypeptide regions derived from an A Subunit of a member of the Shiga toxin family. Certain multivalent CD20-binding molecules of the present invention, and compositions thereof, have uses for selective killing of specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, tumors, and immune disorders.
    Type: Application
    Filed: July 18, 2019
    Publication date: November 28, 2019
    Applicant: Molecular Templates, Inc.
    Inventors: Eric POMA, Erin WILLERT, Jason KIM, Jack HIGGINS, Jensing LIU, Rodney FLORES-LEFRANC
  • Multivalent CD20-binding molecules comprising Shiga toxin A subunit effector regions and enriched compositions thereof
    Patent number: 10392425
    Abstract: The present invention provides multivalent CD20-binding molecules, and compositions thereof, such as enriched compositions comprising large proportions of multivalent CD20-binding molecule relative to monovalent CD20-binding molecule. Certain multivalent CD20-binding molecules of the present invention comprise 1) two or more CD20 binding regions and 2) one or more Shiga toxin effector polypeptide regions derived from an A Subunit of a member of the Shiga toxin family. Certain multivalent CD20-binding molecules of the present invention, and compositions thereof, have uses for selective killing specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, tumors, and immune disorders.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: August 27, 2019
    Assignee: Molecular Templates, Inc.
    Inventors: Eric Poma, Erin Willert, Jason Kim, Jack Higgins, Jensing Liu, Rodney Flores-Lefranc
  • MULTIVALENT CD20-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS AND ENRICHED COMPOSITIONS THEREOF
    Publication number: 20180057544
    Abstract: The present invention provides multivalent CD20-binding molecules, and compositions thereof, such as enriched compositions comprising large proportions of multivalent CD20-binding molecule relative to monovalent CD20-binding molecule. Certain multivalent CD20-binding molecules of the present invention comprise 1) two or more CD20 binding regions and 2) one or more Shiga toxin effector polypeptide regions derived from an A Subunit of a member of the Shiga toxin family. Certain multivalent CD20-binding molecules of the present invention, and compositions thereof, have uses for selective killing specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, tumors, and immune disorders.
    Type: Application
    Filed: February 4, 2016
    Publication date: March 1, 2018
    Applicant: Molecular Templates, Inc
    Inventors: Eric POMA, Erin WILLERT, Jason KIM, Jack HIGGINS, Jensing LIU, Rodney FLORES-LEFRANC
  • MULTIVALENT CD20-BINDING MOLECULE COMPRISING SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND ENRICHED COMPOSITIONS THEREFOF
    Publication number: 20170275382
    Abstract: The present invention provides multivalent CD20-binding molecules, and compositions thereof, such as enriched compositions comprising large proportions of multivalent CD20-binding molecule relative to monovalent CD20-binding molecule. Certain multivalent CD20-binding molecules of the present invention comprise 1) two or more CD20 binding regions and 2) one or more Shiga toxin effector polypeptide regions derived from an A Subunit of a member of the Shiga toxin family. Certain multivalent CD20-binding molecules of the present invention, and compositions thereof, have uses for selective killing specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, tumors, and immune disorders.
    Type: Application
    Filed: October 11, 2016
    Publication date: September 28, 2017
    Applicant: Molecular Templates, Inc.
    Inventors: Eric Poma, Erin Willert, Jason Kim, Jack Higgins, Jensing Liu, Rodney Flores-Lefranc